Tsumura & Co.

Tokyo Stock Exchange 4540.T

Tsumura & Co. EBITDA Margin for the year ending March 31, 2024: 20.40%

Tsumura & Co. EBITDA Margin is 20.40% for the year ending March 31, 2024, a -9.39% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Tsumura & Co. EBITDA Margin for the year ending March 31, 2023 was 22.51%, a -7.61% change year over year.
Tsumura & Co. EBITDA Margin for the year ending March 31, 2022 was 24.37%, a 13.90% change year over year.
Tsumura & Co. EBITDA Margin for the year ending March 31, 2021 was 21.39%, a 4.28% change year over year.
Tsumura & Co. EBITDA Margin for the year ending March 31, 2020 was 20.51%, a -0.32% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tokyo Stock Exchange: 4540.T

Tsumura & Co.

CEO	Mr. Terukazu Kato
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	2-17-11, Akasaka
Employees	4,138
Sector	Health Care
Industries Pharmaceuticals

Description

Tsumura & Co. engages in the manufacture and sale of pharmaceutical products worldwide. The company offers Kampo extract intermediates and granular Kampo formulations. It is involved in the procurement, selection and processing, and storage of raw material crude drugs and crude drug pieces for decoction; manufacture of Kampo powdered extracts and traditional Chinese medicines; and sale of pharmaceuticals and food products. The company was founded in 1893 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years